|
gptkb:Bryostatin_1
|
Phase II
|
|
gptkb:linsitinib
|
Phase III (as of 2014)
|
|
gptkb:Crinetics_Pharmaceuticals
|
Phase 3 (paltusotine)
|
|
gptkb:Moderna_COVID-19_Vaccine
|
July 2020 - November 2020
|
|
gptkb:BIIB122
|
Phase 3
|
|
gptkb:Aducanumab
|
Phase 3
|
|
gptkb:Immunovant,_Inc.
|
warm autoimmune hemolytic anemia
|
|
gptkb:Elucida_Oncology
|
ELU001 for ovarian cancer
|
|
gptkb:ATP7A_gene
|
genetic testing for Menkes disease
|
|
gptkb:PALB2
|
genetic testing for cancer risk
|
|
gptkb:HSP90_inhibitors
|
Phase III
|
|
gptkb:TCR-engineered_T_cell_therapy
|
Phase II
|
|
gptkb:Amyloid_precursor_protein
|
Alzheimer's disease therapies
|
|
gptkb:tipifarnib
|
Phase II
|
|
gptkb:Vir_Biotechnology,_Inc.
|
COMET-ICE
|
|
gptkb:bryostatin
|
yes
|
|
gptkb:SAPIEN_XT
|
gptkb:PARTNER_II_trial
|
|
gptkb:JCAR017
|
Phase 2
|
|
gptkb:COVID-19_vaccine_(in_partnership_with_BioNTech)
|
2020
|
|
gptkb:hsa:6647
|
SOD2 polymorphism and disease risk
|